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and -independent signal pathway
Chunning Zheng1†, Wei Jia2†, Yong Tang2, HuiLiang Zhao2, Yingsheng Jiang1 and Shaochuan Sun1*Abstract
Mesothelin, a secreted protein, is overexpressed in some cancers, including pancreatic cancer. Rescent studies have
shown that overexpression of mesothelin significantly increased tumor cell proliferation, and downregulation of
mesothelin inhibited cell proliferation in pancreatic cancer cells, but its exact function and mechanism remains
unclear. The aim of the present study was to evaluate the effects of mesothelin on proliferation and apoptosis in
pancreatic cancer cells with different p53 status and to explore its signal pathway. Mesothelin levels were detected
by western blot and RT-PCR assay in human pancreatic cancer AsPC-1, HPAC and Capan-2, Capan-1 and MIA
PaCa-2 cell lines. Mesothelin was slienced by shRNA in AsPC-1, Capan-2 and Capan-1 cells with rich mesothelin
level, and mesothelin was overexpressed in the HPAC and Capan-2 cells with less mesothelin level. We observed
that in the AsPC-1 and Capan-1cells with mt-p53, and Capan-2 cells with wt-p53, shRNA mediated sliencing of the
mesothelin significantly increased PUMA and Bax expression and caspase-3 activity, and decreased bcl-2 expression,
followed by the reduced proliferation and colony forming capability and increased cell apoptosis. When PUMA was
slienced by siRNA in the stable mesothelin shRNA transfected cells, proliferative capability was significantly
increased, and apoptosis was decreased. However, in the Capan-2 cells with wt-p53, suppression of the mesothelin
significantly increased wt-p53 levels. When p53 was blocked by siRNA in the stable mesothelin shRNA transfected
Capan-2 cells, PUMA was inhibited, followed by increased proliferative capability and decreased cell apoptosis. In
the HPAC and Capan-2 cells with wt-p53 and in the MIA PaCa-2 cells with mt-p53, overexpression of the
mesothelin significantly decreased bax levels and increased bcl-2 levels, followed by increased proliferative and
colony forming capability. Furthermore, mesothelin-shRNA-transfected cells exhibited a reduced rate of tumor
growth under in vivo conditions. However, mesothelin-transfected cells exhibited a increased rate of tumor growth
under in vivo conditions. Our data demonstrated that mesothelin promotes proliferation and inhibited apoptosis
through p53-dependent pathway in pancreatic cancer cells with wt-p53, and p53-independent pathway in
pancreatic cancer cells with mt-p53. Targeting mesothelin by shRNA is the important method for pancreatic cancer
therapy.
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Pancreatic cancer remains stubbornly resistant to many
key cytotoxic chemotherapeutic agents and novel tar-
geted therapies. Despite intensive efforts, attempts at im-
proving survival in the past 15 years, particularly in
advanced disease, have failed. This is true even with the
introduction of molecularly targeted agents, chosen on
the basis of their action on pathways that were sup-
posedly important in pancreatic cancer development and
progression [1]. Clearly, there is a need to understand
more about the molecular mechanisms of pancreatic
cancer tumorigenesis and to develop effective treatment
strategies for pancreatic cancer.
The mesothelin gene encodes a 69-kDa precursor pro-
tein that is proteolytically cleaved into an Nterminus
secreted form and a C-terminus membrane-bound form,
40-kDa MSLN, which is a glycosylphosphatidylinositol-
linked (GPI)-linked glycoprotein [2]. The normal bio-
logical function of mesothelin is unknown. In one study,
mutant mice that lacked both copies of the mesothelin
gene had no detectable phenotype, and both male and
female mice produced healthy offspring, suggesting that
mesothelin is not involved in normal growth and devel-
opment [3]. It has recently found mesothelin is highly
expressed in many common epithelial cancers. Mesothelin
expression by immunohistochemistry is present in ap-
proximately 100% of epithelial malignant mesotheliomas
and ductal pancreatic adenocarcinomas, 67% to 100% of
ovarian cancers and 41% to 53% of lung adenocarcinomas
[4-8]. In addition,mesothelin is expressed to varying de-
grees by other tumors including cervical, head and neck,
gastric, and esophageal carcinomas [9]. This differential
expression of mesothelin makes it an attractive target for
cancer therapy.
A mesothelin-expressing ascitogenic malignant tumour
model that demonstrates morphological features of in-
traperitoneal tumorigenesis has been created [10]. The
tumour model (WF-3)also demonstrates relatively high
proliferation and migration rates compared with the par-
ental cell line (WF-0). In pancreatic cancer cells, forced
expression of mesothelin significantly increased tumor cell
proliferation and migration by 90% and 300%, respectively,
and increased tumor volume by 4-fold in the nude mice
xenograft model when compared with the vector control
cell line [11]. Several studies based on animal or cell cul-
ture models indicate that mesothelin expression is
involved in the Wnt orβ-catenin signaling pathway, whose
deregulation plays an important role in carcinogenesis
[12-14]. Bharadwaj et al.has shown that mesothelin-
activated NF-κB induces elevated IL-6 expression, which
acts as a growth factor to support pancreatic cancer cell
survival/proliferation through a novel auto/paracrine IL-
6/sIL-6R trans-signaling [15]. Furthermore, mesothelin-
induced pancreatic cancer cell proliferation also involvesalteration of cyclin E via activation of signal transducer
and activator of transcription protein-3 [16], in this study,
overexpressing mesothelin in MIA PaCa-2 cells with mt-
p53 significantly increased cell proliferation and faster cell
cycle progression compared with control cells, and silen-
cing mesothelin in BxPC-3 cells with mt-p53 showed
slower proliferation and slower entry into the S phase than
control cells [16]. Bharadwaj et al.has recently reported
compared to low endogenous mesothelin -expressing
MIA PaCa-2 and Panc 28 cells, high endogenous me-
sothelin -expressing Capan-1(mt-p53), BxPC3(mt-p53),
PL 45, Hs 766 T, AsPC-1(null-p53), Capan-2(wt-p53),
Panc 48 cells were resistant to TNF-α induced growth in-
hibition regardless of the p53 status [17]. However, bio-
logic functions and molecular mechanisms that contribute
to the tumor progression caused by the overexpressed
genes remain largely unknown.
Mesothelin has been implicated as a potential ideal tar-
get antigen for the control of mesothelin-expressing can-
cers such as ovarian cancer, mesothelioma and pancreatic
adenocarcinoma.In pancreatic cancer,silencing of meso-
thelin inhibited cell proliferation and migration in pancre-
atic cancer cells and ablated tumor progression in vivo
and vitro [16]. Vaccination with chimeric virus-like parti-
cles that contain human mesothelin substantially inhibited
tumor progression in C57BL/6 J mice [11]. Otherwise,
knockdown of mesothelin sensitized pancreatic cancer
cells to radiation and TNF-a-induced apoptosis [17,18].
However,the molecular mechanisms of mesothelin slien-
cing on proliferation and apoptosis in pancreatic cancer
cells is unclear.
The transcription factor p53 plays a key role in the DNA
damage response to genotoxic stress by binding directly to
the promoters of target genes and altering the rate at
which they are transcribed. Once activated,p53 induces or
represses various target genes,including proapoptotic Bcl-
2 genes,leading to a myriad of cellular outcomes, including
apoptosis,growth arrest, cellular senescence, and DNA re-
pair. Thus, p53 integrates cellular stress responses, and
loss of p53 function leads to the aberrant proliferation
of damaged cells.It has shown the expression levels of
both Bcl-2 and Mcl-1 proteins significantly increased in
mesothelin-overexpressed WF-0 transfectants. Interest-
ingly, more endogenous mesothelin introduced caused
lower expression of the pro-apoptotic protein Bax. These
results indicate that endogenous mesothelin not only
enhanced the expression of the anti-apoptotic proteins
Bcl-2 and Mcl-1, but also reduced the expression of the
pro-apoptotic protein Bax [10].In the present study,we
study whether mesothelin regulates proliferation and
apoptosis in pancreatic cancer cells through p53-bcl-2/bax
pathway.
One important p53 effector is PUMA (p53-upregulated
modulator of apoptosis) [19]. PUMA is a Bcl-2 homology
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of p53-dependent and -independent apoptosis induced by
a wide variety of stimuli, including genotoxic stress,
deregulated oncogene expression, toxins, altered redox
status, growth factor/cytokine withdrawal and infection. It
serves as a proximal signaling molecule whose expression
is regulated by transcription factors in response to these
stimuli. PUMA transduces death signals primarily to the
mitochondria, where it acts indirectly on the Bcl-2 family
members Bax and/or Bak by relieving the inhibition
imposed by antiapoptotic members. It directly binds and
antagonizes all known antiapoptotic Bcl-2 family members
to induce mitochondrial dysfunction and caspase activa-
tion [20].
It has shown MIA PaCa-2- mesothelin cells showed
increased expression of anti-apoptotic Bcl-xL and Mcl-1,
deactivated (p-Ser75) BAD, and activated (p-Ser70) Bcl-
2,and vice verce [17]. We hypothesis that mesothelin
regulates anti-apoptotic effect via PUMA pathway.
In the present study, we investigated the effect of me-
sothelin overexpression or sliencing on apoptosis and pro-
liferation in pancreatic cancer cells with different p53
status,and disscused the mechanism.
Materials and methods
Cell culture and regents
Human pancreatic cancer cell lines AsPC-1(p53-null),
HPAC and Capan-2(wt-p53), Capan-1 and MIA PaCa-2
(mutant p53)were purchased from the American Type
Culture Collection (ATCC, Rockville, MD). The cells
were routinely cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM). They were all lemented with 10%
fetal bovine serum (FBS) in a 37°C incubator in a hu-
midified atmosphere of 5% CO2. Antibodies against the
p53 (1:200,DO-1), p21(1:200), caspase-3 (1:100) was from
Cell Signaling Technology; PUMA-a(1:200), Mesothelin
(1:250)and goat anti-rabbit IgG antibody conjugated
to horseradish peroxidase was from Santa Cruz
Biotechnology.
Stable mesothelin shRNA transfection
Mesothelin shRNA Plasmid and shRNA encoding non-
effective expression plasmid against GFP (Mock shRNA)
were purchased from Santa Cruz,Shanghai,China.
Mesothelin shRNA (h) is a pool of 3 target-specific 19-25
nt shRNAs designed to knock down gene expression. For
shRNA transfection, AsPC-1and Capan-1/2 cells with rich
mesothelin mRNA were were carried out in a 6-well plate.
When the cells reached 70% confluence, the transfection
process began. Briefly, solution A was prepared by diluting
10 μg of Mesothelin shRNA into 200μL serum-free
medium, and solution B was prepared by diluting 20μL
Lipofectimine 2000 into 200μLserum-free medium. The
two solutions were combined for 20 min at roomtemperature, and then 0.6 mL serum-free medium was
added to the tube containing the complex, and subse-
quently added to the rinsed cells. The medium was
replaced with fresh and complete medium 18 h after the
start of transfection. Forty-two hours after transfection, it
was replaced with the selective G418 (500-600 ug/mL).
Once stable transfections were obtained, the cells were
maintained in G418 (250-300 ug/mL). The cells were
transfected with either the Mock shRNA or Mesothelin
shRNA Plasmid.
Mesothelin plasmid construction and stable transfection
The full-length ORF of human mesothelin (Genbank ac-
cession no. NM 005823)was amplified by PCR from the
cDNA of an pancreatic cancer tissue using sense: 5’-
GCCAATCACCCTGCACATCAGAGTT -3’, antisense:
5’-TTCCCGTTTACTGAGCGCGAGTTCT-3’. Mesothe-
lin cDNA was digested with EcoRI/XbaI and cloned in
the EcoRI/XbaI site of pcDNA3.1 following the manufac-
turer's instructions. Briefly, a tube containing 3 μl of the
plasmid and 100 μl of competent Escherichia coli was
placed on ice for 45 min and then immersed in a 42°C
water bath for 90 s without agitation. After transfer of
800 μl of LB broth, the tube was shaken at 150 r/min for
1 h at 37°C, followed by spreading 200 μl of the suspen-
sion onto each LB plate containing ampicillin and incu-
bation at 37°C for 16 h. After formation of bacterial
colonies, the colonies were picked from the plates and
incubated with 5 ml of LB medium containing ampicillin
for 16 h. For the extraction of plasmid, 1.5 ml of the
bacteria suspension (in an Eppendorf tube) was centri-
fuged at 12000 r.p.m. for 1 min, then treated with Solu-
tion I (50 mmol/l glucose, 25 mmol/l Tris–Cl pH 8.0,
10 mmol/EDTA), Solution II (0.2 N NaOH/1% SDS) and
Solution III (mixture of 5 mol/l potassium acetate, gla-
cial acetic acid and H2O in the ratio of 6:1.15:2.85), re-
spectively, and centrifuged at 12 000 r.p.m for 10 min.
The supernatant was treated with phenol:chloroform
(1:1) and centrifuged at 12000 r.p.m. for 10 min at 0°C,
then placed at −20°C by adding 2 vol of alcohol for 1 h,
followed by centrifugation at 12 000 r.p.m. for 10 min,
removal of supernatant and drying at room temperature.
Then 20 μl of RNase (100 μg/ml) was added to each
tube and incubated at 65°C for 30 min. DNA thus
obtained was electrophoresed on 1% agarose gel. Recom-
binant plasmid was purified by QIA prep spin miniprep
kit (QIAGEN). HPAC, Capan-2 and MIA PaCa-2 cells
were routinely cultured in DMEM media supplemented
with 10% heat-inactivated FBS, 100 μg/ml penicillin and
100 μg/ml streptomycin, and incubated at 37°C in a hu-
midified atmosphere containing 5% CO2 in air. Gene
transfer was performed according to the manufacturer's
protocols. Briefly, 3×105 cells/well containing 2 ml ap-
propriate complete growth medium were seeded in a 6-
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cubator until the cells were 70–80% confluent. A cover
slip was plated in each well before seeding. After the cells
were ringed with serum-free and antibiotics-free medium,
the cells were transfected separately with pcDNA3.1-
mesothelin cDNA μg/lipofectamine 3 μl (experimental
group), pcDNA3.1 1 μg/lipofectamine 3 μl (vector control)
and only lipofectamine 3 μl (mock control), followed by
incubation at 37°C in a 5% CO2 incubator for 6 h. Then
the medium was replaced by DMEM culture medium
containing 20% FBS. After 48 h, two wells in each group
were taken out to detect the transient expression of
mesothelin by western blot methods, whereas others were
continuously cultured for stable expression of mesothelin.
G418 (600-800 mg/l) was added to select the resistant
clones after 48 h. Six days later, when most of the cells
died, the concentration of G418 was decreased to 300-
400 mg/l and cells were cultured for another 6 days. The
medium was changed every 3 or 4 days, and mixed popu-
lation of G418 resistant cells were collected 2 weeks
later for the examination of stable expression of mesothe-
lin by western blot methods and RT–PCR assay.
Transient p53 siRNA and PUMA-a siRNA transfection
Small interfering RNA (siRNA) (20 μl) against p53 was
purchased from Cell Signaling Technology. Small interfe-
ring RNA (siRNA) (10 μl) against PUMA was purchased
from Santa Cruz Biotechnology. For transient transfection,
3.3 nM p53 siRNA,PUMA siRNA and their mock siRNA
was transfected into stable transfected cells for 48 h in 6-
well plates using Lipofectamine 2000 Reagent (Invitrogen)
according to the manufacturer’s instructions. At 48 h after
transfection, the effects of gene silencing were measured
via western blot.
Xenograft tumors and tissue staining
All animal experiments were approved by the Institu-
tional Animal Care and Use Committee at the Shandong
University. Subconfluent stable pancreatic cancer cells
with mesothelin overexpression or shRNA silencing
were harvested by trypsinization, and resuspended in
DMEM. 2×106 cells were inoculated into the right flank
of 5- to 6-week-old male nude mice as described previ-
ously [11]. The subcutaneous tumor model, the tumor
size was measured every week day for 28 days with cali-
pers to calculate tumor volumes according to the for-
mula(length×width2)/2.
In vivo immunohistochemical staining for Ki-67 and
cleaved caspase-3
Tumor samples were fixed in 10% buffered formalin for
12 h and processed conventionally to prepare paraffin-
embedded block. Tumor sections (5 μm thick) were
obtained by microtomy and deparaffinized using xyleneand rehydrated in a graded series of ethanol and finally in
distilled water. Antigen retrieval was done in 10 mmol/L
citrate buffer (pH 6.0) in microwave at closer to boiling
stage followed by quenching of endogenous peroxidase ac-
tivity with 3.0% H2O2 in methanol (v/v). Sections were
incubated with specific primary antibodies, including
mouse monoclonal anti-ki-67 (ki-67; 1:250 dilutions;
DAKO), rabbit polyclonal anti-cleaved caspase-3 (Asp175;
1:100 dilutions; Cell Signaling Technology) for 1 h at 37°C
and then overnight at 4°C in a humidity chamber. Nega-
tive controls were incubated only with universal negative
control antibodies (DAKO) under identical conditions.
Sections were then incubated with appropriate biotiny-
lated secondary antibody (1:200 dilutions) followed with
conjugated horseradish peroxidase streptavidin (DAKO)
and 3,30-diaminobenzidine (Sigma) working solution and
counterstained with hematoxylin. ki-67 -positive (brown)
cells together with total number of cells at 5 arbitrarily
selected fields were counted at ×400 magnification for
the quantification of proliferating cells. The proliferation
index was determined as number of ki-67-positive cells ×
100/total number of cells. Similarly, cleaved caspase-3
staining was quantified as number of positive (brown)
cells × 100/total number of cells in 5 random microscopic
(×400) fields from each tumor, and data are presented as
mean ± SE score of five randomly selected microscopic
(×400) fields from each tumor from all samples in each
group .
RT-PCR assay
Total RNA was isolated from cells or frozen tissues in
all treatment conditions using TRIzol per standard
protocol. Total RNA was treated with DNase I (Invitro-
gen) to remove contaminating genomic DNA. PCR ana-
lysis was done using the onestep reverse transcription–
PCR kit (Invitrogen). GAPDH was used as an internal
control. The following primers were used: Mesothelin:
sense: 5’- AACGGCTACCTGGTCCTAG -3’, antisense:
5’- TTTACTGAGCGCGAGTTCTC -3’. GAPDH: sense:
5’-TGATGGGTGTGAACCACGAG-3’, antisense: 3’-TT
GAAGTCGCAGGAGACAACC-5’. The PCR conditions
consisted of an initial denaturation at 95°C for 3 min,
followed by 30 cycles of amplification (95°C for 15 s, 58°C
for 15 s, and 72°C for 20 s) and a final extension step of
4 min at 72°C. PCR products were analyzed on a 1.5%
agarose gel.
Western blotting
Total cellular proteins from frozen –tissues or cells after
forty-eight hours ‘s transfection of plasmids and shRNA
were isolated and the protein concentration of the
sample was determined by BioRad DC Protein Assay
(Bio-Rad Laboratories Inc., Hercules, CA). Gel electro-
phoresis was performed on a 4-20% sodium dodecyl sulfate
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subsequently transferred to PVDF Immobilon-P membrane
(Millipore) for 1 h at 100 V. Following this, the blot mem-
brane was incubated for 1 h in blocking buffer {5% milk
powder in Tris-buffered saline(TBS)-T buffer [20 mM
Tris–HCl pH 7.5, 500 mM NaCl,0.05% (v/v) Tween 20]}.
The blot membrane was then incubated with an anti-
FLAG horseradish peroxidase-coupled monoclonal anti-
body (Sigma) in TBS-T buffer (1:5000 dilution) for 1 h at
room temperature. The membrane was washed 4× 10 min
in TBS-T buffer. anti-GAPDH (Ambion) was as a loading
control.Determination of cleaved caspase 3 in vitro
Cleaved caspase 3 was determined by fluorogenic sub-
strates according to the manufacturer's instructions. cleaved
caspase 3 was measured fluorometrically at 510 nm on a
microplate fluorescence reader (1420 Victor Multilabel
Counter; Wallac, Rodgau-Jugesheim, Germany).MTT assay
Cell lines treated with shRNA or/and cDNA were plated
at 2 × 103 cells per well in 96-well plates for six days.
Cytotoxicity was determined by 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide assay (MTT, Tre-
vigen,Inc., Gaithersburg, MD) in accordance with the
manufacturer’s instructions. Plates were read using a
Vmax microplate spectrophotometer (Molecular Devices,
Sunnyvale, CA) at a wavelength of 570 nm corrected to
650 nm and normalized to controls. Each independent ex-
periment was done thrice, with 10 determinations for each
condition tested. At identical time points,cells were trypsi-
nized to form a single cell suspension. Intact cells, deter-
mined by trypan blue exclusion, were counted using a
Neubauer hemocytometer (Hausser Scientific, Horsham,
PA). Cell counts were used to confirm MTT results.Colony forming assay
Clonogenic survival analysis was performed for each cell
line after treatment with shRNA or/and mesothelin
cDNA. Briefly, cell lines treated with shRNA or/and
mesothelin cDNA were trypsinized to generate a single-
cell suspension and 1×104 cells were seeded into 60-mm
tissue culture dishes. Dishes were returned to the incu-
bator for 14 days before staining with crystal violet. At
the end of incubation, colonies were stained with 0.005%
crystal violet for 1 h and photographed. Plates were ana-
lyzed using Metamorph,in which 5 × 5 stitched images
were counted and multiplied to give colony counts for
the whole plate. Data from three to four independent
experiments were used to generate the survival curves.In vitro apoptosis assay by flow cytometry
Cells were washed, resuspended in 0.5 mL of PBS, and 1
AL/mL YO-PRO-1, and propidium iodide were added.
Cells were incubated for 30 min on ice and analyzed by
flow cytometry (FACScan, Becton Dickinson,Franklin
Lakes, NJ), measuring fluorescence emission at 530 and
575 nm. Cells stained with the green fluorescent dye
YO-PRO-1 were counted as apoptotic; necrotic cells
stained with propidium iodide. The number of apoptotic
cells was divided by the total number of cells (minimum
of 104 cells), giving the apoptotic fraction. Data were
analyzed using CellQuest software (Becton Dickinson).
All observations were reproduced at least thrice in inde-
pendent experiments.
In vitro and vivo apoptosis assay by TUNEL staining
To evaluate apoptosis in vitro, a terminal deoxynucleotidyl
transferase–mediated deoxyuridine triphosphate nick-end
labeling (TUNEL) assay was done in accordance with the
manufacturer’s instructions (ApopTag kit; Intergen Com-
pany). The invo TUNEL assay was done according to the
methods described previously [21]. The stained sections of
tumors of each group were reviewed, and the Apoptosis
Index, determined by TUNEL staining, was determined
by counting at least 1000 cells in 5 randomly selected
high-power fields (magnification, ×200).
Statistical analysis
Statistical analyses were done with Student’s t-test using
GraphPad Software program (San Diego, CA, USA). Two-
tailed P<0.05 was considered statistically significant.
Results
Expression of mesothelin in human pancreatic cancer cell
lines
We examined mesothelin expression in AsPC-1(p53-null),
HPAC(wt-p53) and Capan-2(wt-p53), Capan-1 and MIA
PaCa-2(mutant p53)human pancreatic cancer cell lines by
western blot and RT-PCR. In protein levels, rich expres-
sion of mesothelin was found in the Capan-1 and AsPC-1
cells, and poor expression was found in the MIA PaCa-2
cells and moderate expression in the Capan-2 cell
(Figure 1A). In mRNA level, rich expression of mesothelin
was found in the Capan-2 and AsPC-1 cells, and poor ex-
pression was found in the HPAC and MIA PaCa-2 cells,
and moderate expression in the Capan-1 cell (Figure 1B).
Generation of mesothelin -expressing or mesothelin
sliencing pancreatic cancer cells
AsPC-1,Capan-1 and Capan-2 cells were transfected
with mesothelin shRNA or mock shRNA. After 2 weeks
of selection with G418, mesothelin -sliencing cells and
vector control cells were obtained for each of the two pan-
creatic cancer cell lines. mesothelin mRNA and protein
Figure 1 Expression of mesothelin in pancreatic cancer cell lines. A. mesothelin protein expression in pancreatic cancer cell lines was
detected by Western blot analysis. B. Mesothelin mRNA in pancreatic tissues as detected by RT-PCR analysis.
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analysis (Figures 2A and B). Mesothelin was knockdown
completely in the two cells.
The MIA PaCa-2, HPAC and Capan-2 cells were trans-
fected with pcDNA3.1 mammalian expression vector con-
taining full-length cDNA encoding human mesothelin, or
with the empty pcDNA3.1 vector. After 2 weeks of selec-
tion with G418, mesothelin-expressing cells and vector
control cells were obtained for each of the three pancre-
atic cancer cell lines. Mesothelin protein expression were
measured by Western blot analysis (Figure 2C). All three
mesothelin -expressing cells expressed high levels of
mesothelin protein, whereas none of the three vector con-
trol cell lines expressed detectably increased levels of
mesothelin protein (Figure 2C).Overexpression of mesothelin increases cell proliferation
in pancreatic cancer cells with wt-p53 by p53-dependent
pathway
To elucidate the role of mesothelin overexpression in
pancreatic cancer cell proliferation, we used the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide (MTT) assay, comparing the cell growth rate among
the mesothelin -overexpressing MIA PaCa-2 stable cell
line, the empty vector MIA PaCa-2 stable cell line, and
the unrelated MIA PaCa-2 cell line. The MTT assay
showed that Mesothelin transfected cells proliferated al-
most 3.1 times faster than the control cells at day 3
(P < 0.05; Figure 3A), and almost 2.6 times faster at day
6 (P < 0.05; Figure 3A). To confirm the role of mesothelin
in cell proliferation, we did the above assay with another
stably mesothelin -overexpressing pancreatic cancer cell
line, Capan-2. The similarity of the results provides fur-
ther evidence for the role of mesothelin in inducing cell
proliferation (Figure 3B). The similarity of the results was
also found in HPAC cells (data not shown).Colony formation assay shown mesothelin overexpres-
sion caused about 50% increase in colony formation in
mesothelin -overexpressing MIA PaCa-2 and Capan-2
stable cell line compared to control or mock transfected
cells at 14 days’ culture,respectively (Figure 3B, P<0.05).
The similarity of the results was found in HPAC cells
(data not shown). This result further suggests the
enhanced cell proliferation ability and survival efficiency
of mesothelin overexpressed cells.
We next investigated the signal transduction mechan-
ism of cell survival and proliferation in these cells of
mesothelin-overexpression. To identify signals activated
by mesothelin, we examined transcription factors p53,
bcl-2,bax and PUMA level in stable mesothelin overex-
pressed cells.In the HPAC (wt-p53) and Capan-2(wt-p53)
cells, mesothelin significantly decreased the p53,bax and
increased bcl-2 levels (Figures 3C and D). Although
PUMA was a little decrease,no significant different was
seen(data not shown). This data indicated mesothelin pro-
motes cell survival and proliferation by p53dependent
pathway in HPAC and Capan-2 cells with wt-p53.
Overexpression of mesothelin increases cell proliferation
in pancreatic cancer cells with mt-p53 by p53-
independent pathway
In the MIA PaCa-2(mutant p53) cells, mesothelin in-
creases bcl-2 levels and decreased bax level,however,the
level of p53 and PUMA was not affected (Figure 4E). This
data indicated mesothelin promotes cell survival and pro-
liferation by p53-independent pathway in MIA PaCa-2
cells with mt-p53
Knockdown of mesothelin expression by shRNA inhibited
cell growth and induced apoptosis
To determine whether mesothelin could be an effective
therapeutic target for pancreatic cancer, the effect of me-
sothelin shRNA on cell growth of the pancreatic cancer
Figure 2 Mesothelin re-expressing or mesothelin sliencing in pancreatic cancer cells. A, Whole-cell lysates from mesothelin shRNA-
transfected pancreatic cancer cells were subjected to SDS-PAGE and immunoblotted with anti- mesothelin antibody. GAPDH was used as a
loading control. B, RT-PCR analysis of total RNA (1 μg) isolated from vector control and mesothelin shRNA -transfected pancreatic cancer cells,
GAPDH was used as a loading control. C, Whole-cell lysates from mesothelin cDNA -transfected pancreatic cancer cells were subjected to
SDS-PAGE and immunoblotted with anti- mesothelin antibody. GAPDH was used as a loading control.
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cancer cells. The reason for choosing these pancreatic
cancer cell lines was due to the fact that these cell lines
showed much higher expression of mesothelin. The cell
viability was determined by MTT, and the effect of
mesothelin shRNA on the growth of cancer cells is shown
in Figure 4A. We found that down-regulation of mesothe-
lin expression significantly caused cell growth inhibition
in the ASPC-1 and CaPan-2 pancreatic cancer cell lines
(Figure 4A, P<0.05,respectively). Similar results was shown
in CaPan-1 cells (data not shown).
Colony formation assay shown mesothelin knockdown
of mesothelin caused 50% and 60% decrease in colony
formation in mesothelin -sliencing ASPC-1 and Capan-2
stable cell line compared to mock transfected cells,re-
spectively (Figure 4B, P<0.05,respectively). This result
further suggests the decreased cell proliferation ability
and survival efficiency of mesothelin down-expressed
cells. Similar results was shown in CaPan-1 cells (data not
shown).
To investigate whether the growth-inhibitory effects of
mesothelin shRNA are partially related to the inductionof apoptosis, the effect of mesothelin shRNA on apoptotic
cell death was examined using an FCM and TUNEL
assay. These results provided convincing data that down-
regulation of mesothelin induces apoptosis in the two
pancreatic cancer cell lines (Figures 4C and D). These data
suggest that the growth-inhibitory activity of mesothelin
down-regulation is partly attributedto an increase in cell
death. Similar results was shown in CaPan-1 cells (data
not shown).
Knockdown of mesothelin suppresses cell survival,
proliferation and promotes apoptosis by p53-dependent
in pancreatic cancer cells with wt-p53
It has shown above mesothelin sliencing suppresses cell
survival and proliferation.We next investigated the signal
transduction mechanism of cell survival and proliferation
in mesothelin-sliencing Capan-1, Capan-2 and ASPC-1
cells with wt- and mt- p53 status. To identify signals acti-
vated by mesothelin sliencing, we examined transcription
factors p53, PUMA, bax and bcl-2. In the Capan-2 cell
with wt-p53 cells, mesothelin sliencing significantly in-
creased the p53, PUMA and bax levels (Figure 5A),
Figure 3 Overexpression of mesothelin promotes pancreatic cancer cell survival and proliferation. A, Cell proliferation of MIA PaCa-2 and
Capan-2 cells according to MTT assay. Stable mesothelin transfected MIA PaCa-2 and Capan-2 cells and control cells were seeded in 96-well
plates (2 × 103 cells/well), serum-starved (0% fetal bovine serum, FBS) for 24 h before changing to 2% FBS growth medium, and cultured for
6 day. Viability was measured with MTT. Relative increase in viability was measured by dividing viability at one time point by viability of the same
cell at day 0 (day of addition of growth medium after initial serum starvation) and is plotted along the Y-axis. Points, mean of triplicate wells.
B, cells grown in soft agar were counted. bars, SD. *, P < 0.05, relative to control or mock(at 14 days). C and D, Mesothelin increases bcl-2 and
decrease Bax via p53-dependent pathway. Whole cell extract from cells were probed for western blot. E, Mesothelin increases bcl-2 and decrease Bax by
p53-independent pathway. Whole cell extract from cells were detected for western blot.
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(Figure 5A). When p53 was knockdown by p53 siRNA
transfection (3 days after transfection) in stable mesothelin-
sliencing cells, PUMA and bax levels (Figure 5B) and
caspase-3 activity (Figure 5B) was significantly decreased.
But the bcl-2 level was increased (Figure 5B). This data
shown mesothelin sliencing decreased PUMA, caspase-3,
bax and increased bcl-2 levels was by p53-dependent path-
way in Capan-1 cells with wt-p53.
Cell survival and proliferation assay shown p53 or
PUMA re-inhibition by siRNA in stable mesothelin slien-
cing Capan-2 cells promotes cell survival and proliferation
(Figure 5C). This data shown mesothelin sliencing inhi-
bited cell survival and proliferation was by p53-dependent
pathway in Capan-2 cells with wt-p53. Similar results was
shown in HAPC cells (data not shown).
PUMA is a Bcl-2 homology 3 (BH3)-only proapoptotic
Bcl-2 family member and mediates p53-dependent and
-independent apoptosis.In our study, PUMA is moderate
in Capan-2 cells, mesothelin sliencing significantlyincreased the PUMA levels (Figure 5A) and caspase-3 ac-
tivity (Figure 5B) followed by rapid and profound apop-
tosis (Figure 5D), and PUMA re-inhibition by PUMA
siRNA transfection in mesothelin sliencing Capan-2 cells
lead to decreased apoptosis (Figures 5D and E). This data
shown mesothelin sliencing promotes apoptosis was
by p53-dependent PUMA pathway in Capan-2 cells
with wt-p53. Similar results was shown in HAPC cells
(data not shown).
Knockdown of mesothelin suppresses cell survival,
proliferation and promotes apoptosis by p53-
independent in pancreatic cancer cells with mt-p53
In ASPC-1 cells with mt-p53, mesothelin sliencing signifi-
cantly increased PUMA and bax levels (Figure 5F) and
caspase-3 activity (Figure 5B), but decreased bcl-2 levels
(Figure 5F). PUMA re-inhibition by PUMA siRNA trans-
fection in mesothelin-sliencing ASPC-1 cells lead to
increased survival (Figure 6C), decreased apoptosis
(Figures 5D and E) and caspase-3 activity (Figure 5B). This
Figure 4 Mesothelin sliencing suppresses cell survival, proliferation and promotes apoptosis. A, Cell viability was reduced upon
mesothelin sliencing in ASPC-1 and Capan-2 cells. B, Number of colony formation was reduced upon mesothelin sliencing in ASPC-1 and Capan-
2 cells. C, Apoptotic percentages of FCM assays in mesothelin sliencing in ASPC-1 and Capan-2 cells. D, Apoptotic percentages of TUNEL assays in
mesothelin sliencing in ASPC-1 and Capan-2 cells. Results are means±S.E.M. *P < 0.05.
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inhibits survival was by p53-independent pathway in
ASPC-1 cells with mt-p53. Similar results was shown in
CaPan-1 cells(data not shown).
Mesothelin contributes to pancreatic cancer progression
in the nude mouse xenograft model
Li et al [11]has reported mesothelin significantly in-
creased tumor cell proliferation in MIA PaCa-2(mutant
p53)human pancreatic cancer cell, and mesothelin shRNA
significantly decreased tumor cell proliferation in BxPC-3
(mutant p53)human pancreatic cancer cell in vivo and
vitro. In the present study, we investigated the effect of
Mesothelin sliencing or overexpression on human pancre-
atic cancer cell lines AsPC-1(p53-null), HPAC and Capan-
2(wt-p53), Capan-1 and MIA PaCa-2 (mutant p53)
in vivo, and discussed the mechanism. MIA PaCa-2(mt-
p53)- mesothelin cells showed a dramatic increase (3.0-
fold) in tumor volume over MIA PaCa-2 -mock control
cells in the subcutaneous tumor model (p < 0.01,
Figure 6A), this was similar to Li’s study [11]. Similarly,
CaPan-2- mesothelin (wt-p53) cells significantly increased
tumor size by 2.4-fold after 4 weeks compared with mock
control cells (p < 0.01, Figure 6A), however, no significant
increase was shown in HPAC cells (p > 0.05, Figure 6A).
In contrast, ASPC-1-shRNA mesothelin cells with
reduced mesothelin expression showed a significant re-
duction in tumor volume compared with mock controlcells (p < 0.01, Figure 6B). Similarly, CaPan-1- shRNA
mesothelin (mt-p53) cells significantly decreased tumor
size by 3.4-fold, and CaPan-2- shRNA mesothelin
(wt-p53) cells significantly decreased tumor size after
4 weeks compared with mock control cells (p < 0.01,
Figure 6B).
Next we examined pancreatic cancer tumors by immu-
nohistochemical methods for the possible antiprolifera-
tive, and proapoptotic effects of mesothelin that could
have mediated its overall antitumor efficacy. The micro-
scopic examination of ki-67 staining of tumors showed
weak ki-67 immunoreactivity in mesothelin shRNA trea-
ted ASPC-1, CaPan-1 and Capan-2 groups compared
with control group,however, strong staining in ki-67
immunoreactivity in mesothelin treated Capan-2, MIA
PaCa-2 groups compared with control group,except for
HPAC groups (Figure 6C). In the present study, we
observed marked inhibitory effect of mesothelin shRNA
on bcl-2,and marked promoting effect of mesothelin on
bcl-2 (Figure 6D).
Mesothelin shRNA also showed an increase in PUMA
and bax levels (Figure 6D) and TUNEL-positive cells in
tumors (Figure 6E), the quantification of which showed
a 5, 5.0 and 7-fold (P < 0.05) increase in apoptotic index
in ASPC-1, CaPan-1 and Capan-2 cells compared with
the control group of tumors (Figure 6D).
Next, tumors were analyzed for cleaved caspase-3 im-
munostaining (Figure 6F), in which Mesothelin shRNA
Figure 5 (See legend on next page.)
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Figure 5 Mesothelin sliencing suppresses cell survival,proliferation and promotes apoptosis by p53-dependent and -independent
pathway in pancreatic cancer cells. A, Western blot assay for p53, PUMA,bax and bcl-2 in Capan-2 cells with wt-p53. Mesothelin sliencing
significantly increased the P53,PUMA and bax levels and decreased bcl-2 level. Knockdown of p53 by shRNA(3 days transfection) decreased the
PUMA and bax level and increased the bcl-2 level in stable mesothelin silenced CaPan-2 cells. B, Determination of caspase-3 activity. Caspase-3
activity was determined by fluorogenic substrates. Caspase-3 activity was measured fluorometrically at 510 nm on a microplate fluorescence
reader. Mesothelin sliencing significantly increased the caspase-3 activity. The activity in mock shRNA transfected cells was defined 1.* denote
p < 0.05, compared with mock shRNA controls, t test. C, Cytotoxicity assay was by MTT. .* denote p < 0.05,**p<0.01, compared with mesothelin
shRNA groups, t test. D, Cell apoptosis was determined by FCM assay in samples treated with mesothelin shRNA or mesothelin shRNA plus PUMA
shRNA. E, Cell apoptosis was determined by TUNEL assay in samples treated with mesothelin shRNA or mesothelin shRNA plus PUMA shRNA.*
denote p < 0.05, compared with combined shRNA treatment groups, t test. F, Western blot assay for p53, PUMA,bax and bcl-2 in ASPC-1 cells
with mt-p53. Mesothelin sliencing significantly increased the PUMA and bax levels and decreased the bcl-2 level.
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cleaved caspase-3-positive cells over that of control group.
These results confirmed the apoptotic effect of Mesothelin
shRNA in tumors, which could have been mediated by the
caspase-3 pathway.
Our results shown in Capan-2 cells with wt-p53,
mesothelin regulated PUMA, bax and bcl-2 through wt-
p53 dependent pathway. In Capan-1, MIA PaCa-2 and
ASPC-1 cells with mt-p53, mesothelin regulated PUMA,
bax and bcl-2 through wt-p53 independent pathway
(Figure 6D).Discussion
Mesothelin is a glycoprotein to be largely restricted to
mesothelial cells or to epithelial cells of the trachea, ton-
sils, fallopian tube, and kidneys [21]. Mesothelin has been
reported to be a tumour-associated marker in several
types of human cancers, including ovarian carcinomas
and adenocarcinomas arising from the pancreatico-biliary
tract, endometrium, and lungs [22]. Mesothelin has also
been reported to interact with CA125 to mediate cell ad-
hesion [23]. Although the biological functions of mesothe-
lin remain largely unknown, there is evidence that
mesothelin has the potential as a new cancer biomarker
[10] and as a target molecule for gene therapy [24]. Some
investigators have reported that mesothelin can be a new
marker for the diagnosis of ovarian carcinoma [25] and as
a target in mesothelin-expressing tumours [18], including
pancreatic cancer [11]. However,the signal transduction
pathways induced by mesothelin resulting in cell survival
is unclear.
In the present study, we have shown that mesothelin
was overexpressed in the human pancreatic cancer cell
lines. Increased mesothelin is associated with increased
cell proliferation of pancreatic cancer cells in vitro and
contributes to tumor progression in the nude mouse
xenograft model. Silencing of mesothelin expression sig-
nificantly decreased cell proliferation and promoted
apoptosis in pancreatic cancer cells in vitro and inhibited
tumor growth in vivo. We also shown mesothelinmediated cell survival and apoptosis by p53-dependent
and independent conditions.
p53 is a critical regulator of the response to DNA dam-
age and oncogenic stress. Loss of p53 function, through
mutation or deletion, is a frequent occurrence in human
malignancies. Previous experimental works have con-
verged to indicate that the wt-p53 protein would act as a
negative regulator of cell growth [26-28] and a suppressor
of transformation and tumonigenesis [29].
In the study reported here, we chose HPAC cells
which expressed wt-p53 with less endogenous mesothe-
lin, and Capan-2 cells which expressed wt-p53 with
moderate endogenous mesothelin. We found that
mesothelin overexpression in HPAC and Capan-2 cells
is associated with increased cell proliferation followed by
decreased wt-p53. p53 re-inhibition by siRNA in stable
mesothelin sliencing Capan-2 and HPAC cells promoted
cell survival and proliferation.
It has shown the expression levels of both Bcl-2 and
Mcl-1 proteins significantly increased in mesothelin-
overexpressed WF-0 transfectants. Interestingly, more en-
dogenous mesothelin introduced caused lower expression
of the pro-apoptotic protein Bax. These results indicate
that endogenous mesothelin not only enhanced the ex-
pression of the anti-apoptotic proteins Bcl-2 and Mcl-1,
but also reduced the expression of the pro-apoptotic pro-
tein Bax [10]. In the present study,we also observed
increased bcl-2 expression and decreased bax expression
followed by mesothelin overexpression,and vice verse.
Furthermore,the expression of bcl-2/bax was p53-
dependent. This data shown mesothelin promoted cell
survival and proliferation by p53-dependent pathway in
pancreatic cancer cells with wt-p53. However, mesothelin
did not affect proliferation in HPAC cells in vivo, which
suggests that the tumor microenvironment may play an
important role.
In MIA PaCa-2 cells with mutant p53 which expressed
less endogenous mesothelin,we found that mesothelin
overexpression is also associated with increased cell prolif-
eration followed by decreased bax and increased bcl-2. In
contrast, in AsPC-1 cells with p53-null and Capan-1 cells
Figure 6 Effects of mesothelin on pancreatic cancer growth in the xenograft nude mouse model. A. Subcutaneous tumor volume of
HPAC- mesothelin,Capan-2- mesothelin and MIA PaCa-2- mesothelin and their mock cells(2 × 106)were subcutaneously inoculated into nude
mice (8 mice per treatment group). Tumor size was measured weekly for 4 weeks. **p < 0.05,*p>0.05. B. Subcutaneous tumor volume of AsPC-1-
shRNA mesothelin, Capan-2-shRNA mesothelin and Capan-1-shRNA mesothelin (2 × 106) were injected into the flank of nude mice (eight per
treatment group). Tumor size was measured weekly for 4 weeks. **p < 0.05. C, Ki-67-positive cells were counted under ×400 magnifications in five
randomly selected areas in each tumor sample. Mean ± SE of 8 tumor samples from individual mouse in each group. D, Mesothelin,P53,PUMA,
bax and bcl-2 protein was detected by Western blot in tumor samples. E, Mesothelin regulates cell apoptosis in orthotopic pancreatic cancer
tumors. TUNEL-positive cells were counted under ×400 magnifications in five randomly selected areas in each tumor sample. Mean±SE of 8
tumor samples from individual mouse in each group. F, Cleaved capase-3-positive cells were counted under ×400 magnifications in five
randomly selected areas in each tumor sample. Mean ± SE of 8 tumor samples from individual mouse in each group.
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reduction in expression of mesothelin by shRNA stable si-
lencing resulted in decreased cell proliferation and
increased bax and decreased bcl-2. When mesothelin was
re-expressed in stable mesothelin sliencing cells, cell prolif-
eration and bax expression was increased and bax was
decreased(data not shown). However mesothelin did not
affect wt-p53 level. Those results indicate that in pancreaticcancer cells with mt-p53 or null-p53, mesothelin regulates
proliferation through p53-independent bcl-2/bax pathway.
p53 functions to regulate several pathways, including
cell cycle arrest, DNA repair and apoptosis through
transcriptional upregulation of proapoptotic Bcl-2 genes,
in particular Puma/Bbc3 [30,31]. Loss of p53 protects
cells from p53-dependent apoptotic stimuli due to lim-
ited PUMA transcriptional upregulation. The induction
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particularly in those cells which acquire other oncogenic
lesions [32]. p53-dependent Puma upregulation has a
central role in this response, inducing apoptosis in the
transformed cells [20].
In the present study, silencing endogenous mesothelin
by shRNA in Capan-2 (wt-p53) cells increased signifi-
cant apoptosis followed by increased wt-p53, PUMA and
caspase-3 activity. When the p53 or PUMA was blocked
by transient p53 siRNA or PUMA siRNA transfection in
stable mesothelin shRNA transfected Capan-2 cells,the
significant reduction of apoptosis was found. In vivo,
mesothelin shRNA also promoted apoptosis, followed by
increased p53, PUMA expression and caspase-3 activity.
Those results indicate that mesothelin silencing pro-
moted apoptosis through p53-dependent PUMA path-
way in cells with wt-p53.
However, in AsPC-1(p53-null) and Capan-1 (mutant
p53) cells which expressed rich endogenous mesothelin,
silencing mesothelin by shRNA also increased significant
apoptosis followed by increased PUMA and caspase-3
activity, and PUMA blocked by transient PUMA siRNA
transfection reduced apoptosis,no wt-p53 expression was
found. The same result was found in vivo. Those results
indicate that mesothelin silencing promoted apoptosis
through p53-independent pathway in cells with null/mt-
p53.
In addition to p53, a number of other transcription
factors are implicated in PUMA induction. The p53
homologue p73 can regulate PUMA expression inde-
pendent of p53 by binding to the same p53-responsive
elements in the PUMA promoter in response to a variety
of stimuli [33,34]. On the other hand, PUMA transcrip-
tion is subject to negative regulation by transcriptional
repressors, including Slug [35].In the present study,
whether PUMA was regulated by other factors need fur-
ther investigation.
Conclusion
The present findings provide evidence of a novel biological
function for mesothelin and a mechanism by which
mesothelin ptomotes proliferation and inhibited apoptosis
through p53-dependent pathway in pancreatic cancer cells
with wt-p53, and p53-independent pathway in pancreatic
cancer cells with mt-p53 or null-p53. Those results indicate
that mesothelin is an important factor in pancreatic cancer
growth and a potential target for pancreatic cancer treat-
ment. The significant reduction in pancreatic cancer
growth by mesothelin shRNA indicated the importance of
shRNA blockage and opened a door for shRNA pancreatic
cancer therapy that targets MSLN.
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